271 related articles for article (PubMed ID: 33117836)
1. Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.
Hanna RM; Tran NT; Patel SS; Hou J; Jhaveri KD; Parikh R; Selamet U; Ghobry L; Wassef O; Barsoum M; Bijol V; Kalantar-Zadeh K; Pai A; Amin A; Kupperman B; Kurtz IB
Front Med (Lausanne); 2020; 7():579603. PubMed ID: 33117836
[TBL] [Abstract][Full Text] [Related]
2. Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration.
Phadke G; Hanna RM; Ferrey A; Torres EA; Singla A; Kaushal A; Kalantar-Zadeh K; Kurtz I; Jhaveri KD
Clin Kidney J; 2021 Oct; 14(10):2158-2165. PubMed ID: 34603693
[TBL] [Abstract][Full Text] [Related]
3. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy.
Shye M; Hanna RM; Patel SS; Tram-Tran N; Hou J; Mccannel C; Khalid M; Hanna M; Abdelnour L; Kurtz I
Clin Kidney J; 2020 Dec; 13(6):969-980. PubMed ID: 33391740
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab.
Hanna RM; Abdelnour L; Hasnain H; Selamet U; Kurtz I
SAGE Open Med Case Rep; 2020; 8():2050313X20907033. PubMed ID: 32110410
[TBL] [Abstract][Full Text] [Related]
5. Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema.
Kikuchi Y; Odashima Y; Yoshikawa K; Oda T; Tanaka F; Oikawa H; Ishigaki Y; Asahi K
BMC Nephrol; 2022 Oct; 23(1):348. PubMed ID: 36309669
[TBL] [Abstract][Full Text] [Related]
6. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
[TBL] [Abstract][Full Text] [Related]
8. Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections.
Ahmed M; Alouch N; Ahmed A; Jagadesh SK
Proc (Bayl Univ Med Cent); 2021 Mar; 34(4):527-529. PubMed ID: 34219948
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review.
Hanna RM; Ahdoot RS; Kim MS; Jhaveri KD; Kalantar-Zadeh K; Kurtz IB
Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):47-56. PubMed ID: 34750330
[TBL] [Abstract][Full Text] [Related]
10. Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Tsao YC; Chen TY; Wang LA; Lee CC; Lee WA; Hsu SM; Lai CC; Shao SC; Hung JH; Lai EC
BioDrugs; 2023 Nov; 37(6):843-854. PubMed ID: 37676536
[TBL] [Abstract][Full Text] [Related]
11. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.
Hanna RM; Lopez EA; Hasnain H; Selamet U; Wilson J; Youssef PN; Akladeous N; Bunnapradist S; Gorin MB
Clin Kidney J; 2019 Feb; 12(1):92-100. PubMed ID: 30746134
[TBL] [Abstract][Full Text] [Related]
12. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.
Izzedine H; Escudier B; Lhomme C; Pautier P; Rouvier P; Gueutin V; Baumelou A; Derosa L; Bahleda R; Hollebecque A; Sahali D; Soria JC
Medicine (Baltimore); 2014 Nov; 93(24):333-339. PubMed ID: 25500702
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.
Cheungpasitporn W; Chebib FT; Cornell LD; Brodin ML; Nasr SH; Schinstock CA; Stegall MD; Amer H
Transplantation; 2015 Nov; 99(11):2382-6. PubMed ID: 25905984
[TBL] [Abstract][Full Text] [Related]
14. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury.
Touzani F; Geers C; Pozdzik A
Case Rep Nephrol; 2019; 2019():2919080. PubMed ID: 31934470
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
20. Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice.
Del Cura Mar P; Carballés MJC; Sastre-Ibáñez M
Indian J Ophthalmol; 2023 Aug; 71(8):3091-3094. PubMed ID: 37530286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
